IceCure Medical shareholders approve meeting agenda

IceCure Medical Ltd. convened a Special General Meeting of Shareholders on August 6, 2026.

Rhea-AI Filing Summary

IceCure Medical Ltd. convened a Special General Meeting of Shareholders on August 6, 2026. The meeting was initially adjourned at 5:00 p.m. (Israel time) because a quorum was not present, but the adjourned meeting was held at 6:30 p.m. (Israel time) once a quorum was reached.

At the adjourned meeting, shareholders voted on and approved the agenda item described in the proxy statement furnished to the SEC on July 2, 2026. The Form 6-K is incorporated by reference into the company’s registration statements on Form F-3 (File Nos. 333-297030, 333-290046 and 333-258660) and Form S-8 (File Nos. 333-270982, 333-264578, 333-262620 and 333-281587).

Key Figures

Special General Meeting date: August 6, 2026 Initial meeting time: 5:00 p.m. (Israel time) Adjourned meeting time: 6:30 p.m. (Israel time) +3 more

6 metrics

Special General Meeting date August 6, 2026 Date the Special General Meeting of Shareholders was convened

Initial meeting time 5:00 p.m. (Israel time) Time at which the meeting was first opened but adjourned for lack of quorum

Adjourned meeting time 6:30 p.m. (Israel time) Time at which the adjourned meeting was held with quorum present

Commission File Number 001-40753 SEC commission file number for IceCure Medical Ltd.

Form F-3 file numbers 333-297030, 333-290046, 333-258660 Registration Statements on Form F-3 into which the Form 6-K is incorporated

Form S-8 file numbers 333-270982, 333-264578, 333-262620, 333-281587 Registration Statements on Form S-8 into which the Form 6-K is incorporated

Key Terms

Special General Meeting of Shareholders, quorum, incorporated by reference, Report of Foreign Private Issuer, +2 more

6 terms

Special General Meeting of Shareholders regulatory

"convened a Special General Meeting of Shareholders (the “Meeting”)"

quorum regulatory

"initially adjourned due to there not being a required quorum present"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

incorporated by reference regulatory

"Form 6-K is incorporated by reference into the Company’s Registration Statements"

Report of Foreign Private Issuer regulatory

"This Report of Foreign Private Issuer on Form 6-K is incorporated by reference"

A report of a foreign private issuer is a formal filing that a non‑U.S. company makes to U.S. regulators to share important business, financial, or governance information with American investors. Think of it as a regular update or press packet that keeps investors informed about events that could change a company’s value—like earnings, management changes, contracts, or regulatory developments—so investors can make timely, informed decisions.

Registration Statements on Form F-3 regulatory

"into the Company’s Registration Statements on Form F-3 (File Nos. 333-297030"

Form S-8 regulatory

"and Form S-8 (File Nos. 333-270982, 333-264578, 333-262620 and 333-281587)"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IceCure Medical (ICCM) shareholders approve at the August 6, 2026 Special General Meeting?

Shareholders approved the single agenda item presented at the adjourned meeting. The item was described in IceCure Medical’s July 2, 2026 proxy statement filed with the SEC, which set out the details of the proposal submitted for approval.

Why was IceCure Medical's August 6, 2026 Special General Meeting initially adjourned?

The meeting was adjourned because a quorum was not present at the initial start time of 5:00 p.m. (Israel time). Without a quorum, the company could not open or conduct the meeting, requiring it to reconvene later that evening.

When was quorum achieved for IceCure Medical (ICCM) on August 6, 2026?

Quorum was achieved at the adjourned meeting held at 6:30 p.m. (Israel time). With sufficient shareholder presence at that later time, the company was able to open the meeting, hold votes, and approve the agenda item.

How is this IceCure Medical (ICCM) Form 6-K used in its SEC registration statements?

The Form 6-K is incorporated by reference into IceCure Medical’s registration statements on Form F-3 and Form S-8. This means the disclosed information becomes part of File Nos. 333-297030, 333-290046, 333-258660, 333-270982, 333-264578, 333-262620 and 333-281587.

Which SEC annual report form does IceCure Medical (ICCM) use as a foreign private issuer?

IceCure Medical files its annual reports under cover of Form 20-F. This is the standard SEC annual reporting form for foreign private issuers, providing audited financial statements and key disclosures for each fiscal year.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 04:07 PM Accepted by SEC EDGAR 08/06/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F           ☐ Form 40-F

CONTENTS

On August 6, 2026, IceCure Medical Ltd. (the “Company”) convened a Special General Meeting of Shareholders (the “Meeting”).

The Meeting was initially adjourned due to there not being a required quorum present to open and conduct it at the initial time of 5:00 p.m. (Israel time). However, the adjourned Meeting was eventually held at 6:30 p.m. (Israel time). At the adjourned Meeting, a quorum was present and the shareholders of the Company voted upon and approved the agenda item that was described in the Company’s proxy statement for the Meeting, which was included in Exhibit 99.2 to the Company’s Report of Foreign Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission (“SEC”) on July 2, 2026 (the “Proxy Statement”).

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-297030, 333-290046 and 333-258660) and Form S-8 (File Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IceCure Medical Ltd.
Date: August 6, 2026	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

2